Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Emavusertib-Focused Research Is Poised to Expand the PCNSL Treatment Paradigm

October 4th 2024

Grzegorz S. Nowakowski, MD, discusses the unique mechanism of action of emavusertib and highlights the phase 1/2 TakeAim Lymphoma trial in PCNSL.

Dr Nowakowski on Unmet Needs to be Addressed in R/R Follicular Lymphoma

September 13th 2024

Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.

Challenges With CAR T-Cell Therapies in T-Cell Lymphomas

September 11th 2024

Jasmine M. Zain, MD, of City of Hope, discuss challenges in CAR-T therapies in patients with T-cell lymphomas.

Dr Nowakowski on Monitoring Epcoritamab-Associated ICANS and CRS in Follicular Lymphoma

September 10th 2024

Grzegorz S. Nowakowski, MD, discusses toxicity monitoring strategies for epcoritamab treatment in relapsed/refractory follicular lymphoma.

Dr Nowakowski on the Potential Benefit of Epcoritamab in Relapsed/Refractory FL

September 9th 2024

Grzegorz S. Nowakowski, MD, discusses how epcoritamab may fill an unmet need for patients with relapsed/refractory follicular lymphoma.

Real-World Outpatient CAR T-Cell Administration Insights Show Improved Safety and Feasibility in NHL

September 9th 2024

Radhika Bansal, MBBS, discusses data showing the safety and feasibility of outpatient CAR T-cell infusion in relapsed/refractory non-Hodgkin lymphoma.

Brentuximab Vedotin Triplet Continues to Improve R/R Diffuse Large B-Cell Lymphoma Outcomes

September 7th 2024

Brentuximab vedotin plus lenalidomide/rituximab significantly improved outcomes vs lenalidomide/rituximab alone in relapsed/refractory DLBCL.

Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma

September 7th 2024

Golcadomide given at 0.4 mg plus R-CHOP elicited a high rate of metabolic responses in patients with previously untreated aggressive B-cell lymphoma.

Histologic Distinctions and Optimized Imaging Carve New Paths for Individualized PTCL Management

September 7th 2024

Neha Mehta-Shah, MD, MSCI, discusses unmet needs and future developments in the treatment of patients with peripheral T-cell lymphoma.

Subcutaneous Rituximab Remains Underutilized in Non-Hodgkin Lymphoma

September 6th 2024

The uptake of subcutaneous rituximab has lagged behind the use of the intravenous version in non-Hodgkin lymphoma.

Valemetostat Demonstrates Clinically Meaningful Efficacy in R/R PTCL

September 6th 2024

Treatment with valemetostat demonstrated activity and was tolerable in patients with relapsed/refractory peripheral T-cell lymphoma.

Dr Merryman on the Evolution of MRD Assays in Lymphoma

September 5th 2024

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Dr Kebriaei on the Potential Shift Away From Transplant in ALL

September 5th 2024

Partow Kebriaei, MD, discusses the potential shift away from transplant in acute lymphoblastic leukemia in light of ongoing advancements.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

September 5th 2024

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Dr Smith on Bispecific Antibodies for the Management of R/R Follicular Lymphoma

September 4th 2024

Sonali M. Smith, MD, discusses the current arsenal of bispecific antibodies available for the management of relapsed/refractory follicular lymphoma.

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

September 4th 2024

Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.

Azer-Cel Produces CRs in R/R DLBCL After Prior Autologous CAR T-Cell Therapy

September 3rd 2024

Azercabtagene zapreleucel produced complete responses in relapsed/refractory diffuse large B-cell lymphoma after prior autologous CAR T-cell therapy.

EU Greenlights Odronextamab for R/R Follicular Lymphoma and DLBCL

August 26th 2024

The European Commission approved odronextamab for patients with relapsed/refractory FL or DLBCL who have received at least 2 prior lines of therapy.

Dr Shouse on AEs Associated With Targeted Therapies in FL

August 20th 2024

Geoffrey Shouse, DO, PhD, discusses adverse effects associated with targeted therapies used to treat patients with follicular lymphoma.

Epcoritamab Wins EU Approval for Relapsed/Refractory Follicular Lymphoma

August 20th 2024

The European Commission has granted conditional marketing authorization to epcoritamab for patients with relapsed or refractory follicular lymphoma.